What is the “Norvir patent thicket”?
“Norvir” is the brand name for ritonavir, an HIV medicine. A “patent thicket” is the dense web of overlapping patents, patent-life events, and follow-on claims that can slow or complicate the approval and launch of generic or biosimilar alternatives. For Norvir, the term is commonly used to describe how multiple layers of intellectual-property claims were asserted over time, making it harder for challengers to move quickly from regulatory filing to market entry.
Which patents and claims typically create the thicket?
Patent thickets usually come from several categories of intellectual-property protection that can overlap for the same drug:
- Primary composition-of-matter and related claims (covering the active ingredient).
- Formulation and dosage-form claims (how the drug is made or presented).
- Use-related claims (how the drug is used, including specific therapeutic regimens).
- Secondary protections that can extend commercial exclusion through later-expiring patents or litigation.
The practical effect is that even when one patent expires, others can still block or delay generic entry.
How does this affect generic entry and FDA approval?
When a company files an abbreviated pathway (for example, seeking approval for a generic), it may still need to resolve patent issues listed for the reference drug. If patents are still in force or asserted, the dispute can delay launch even if regulatory reviews are otherwise favorable. In the Norvir context, the thicket concept points to multiple hurdles rather than a single “last patent” date.
Why do these disputes often end up in court?
Companies seeking market entry generally argue that certain patents are invalid, unenforceable, or not infringed. Brand-name manufacturers generally argue the opposite and may seek injunctions or other relief to prevent launch during the dispute. With a thicket, challengers can face a sequence of related or overlapping cases, not one clean fight.
When people look up “Norvir patent thicket,” what are they usually trying to find?
Common search targets include:
- The earliest dates when specific patents expired.
- How long generic entry was delayed versus the first plausible entry date.
- Which litigations or settlements occurred and what they required (often including “design-around” strategies).
- Whether later patents prevented entry even after earlier protections ended.
What outcomes usually resolve a patent thicket?
Thickets typically unwind through one or more of the following:
- Patent expiration (no further litigation needed).
- Court decisions narrowing the number of enforceable, relevant patents.
- Licensing or settlement agreements that allow entry at a particular time or under specific conditions.
- Regulatory and labeling changes that aim to avoid infringement of use-related claims.
Are there broader lessons for other HIV drugs?
Yes. Norvir is often cited (conceptually) as an example of how follow-on patenting and litigation can create long-running exclusivity barriers for older drugs—especially in high-value chronic therapies where market entry timing matters.
Sources needed to answer precisely (patent-by-patent or case-by-case)
To give an accurate, patent-specific description of the Norvir thicket (which patents, which dates, which cases, and what each did to delay entry), I need the specific jurisdiction and the references you want covered (for example, FDA Orange Book patents for Norvir, or particular court dockets).